Yaygın İlaca Dirençli Tüberküloz için Son ve Yeni Stratejiler

Global Tuberculosis Report WHO, 2016. Available from: http://apps.who.int/ medicinedocs/en/d/Js23098en/

Global Tuberculosis Report WHO, 2017. Last accessed date: 01.03.2018. Available from: https://www.who.int/tb/publications/global_report/ gtbr2017_main_text.pdf

WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision.

Komurcuoglu B, Senol G, Balci G, Yalnız E, Ozden E. Drug resistance in pulmonary tuberculosis in new and previously treated cases: experience from Turkey. J Infect Public Health. 2013;6:276-82.

Ozkara S. MDR/XDR TB Definition, Dimension of the Problem in the World and in Turkey. Turkiye Klinikleri J Pulm Med-Special Topics. 2015;8:80-6.

Türkiye"de Verem Savaşı 2017 Raporu. In: İlter H (ed). Sağlık Bakanlığı Yayın No: 1091. Neyir Matbaacılık, Ankara, 2017. Last accessed date: 01.03.2018. Available from: https://hsgm.saglik.gov.tr/depo/haberler/verem-savasraporu- 2016-2017/Turkiyede_Verem_Savasi_2017_Raporu.pdf

Sloan DJ, Lewis JM. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Trans R Soc Trop Med Hyg. 2016;110:163-72.

Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB. Treatment outcomes of patients with multidrug- and extensive drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014;59:1364-74.

Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems. Int J Infect Dis. 2015;32:118-23.

Global tuberculosis report. Geneva: World Health Organization; 2014. Last accessed date: 01.03.2018. Available from: http://apps.who.int/ medicinedocs/documents/s21634en/s21634en.pdf

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D"Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia- Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O"Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9:e1001300.

Lytvynenko N, Cherenko S, Feschenko Y, Pogrebna M, Senko Y, Barbova A, Manzi M, Denisiuk O, Ramsay A, Zachariah R. Management of multi and extensively drug-resistant tuberculosis in Ukraine: how well are we doing? Public Health Action. 2014;4(Suppl 2):S67-S72.

Deshmukh RD, Dhande DJ, Sachdev K, Sreenivas A, Kumar AM, Satyanarayana S, Parmar M, Moonan PK, Lo TQ. Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB centre in India. PLoS One. 2015;10:e0135802.

Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80.

Brigden G, Nyang"wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR Jr, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014;92:68-74.

Prasad R, Gupta N, Balasubramanian V, Singh A. Multidrug resistant tuberculosis treatment in India. Drug Discov Ther. 2015;9:156-64.

Sullivan T, Ben Amor Y. Global introduction of new multidrug-resistant tuberculosis drugs-balancing regulation with urgent patient needs. Emerg Infect Dis. 2016;22:e151228.

Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrugresistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-92.

Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. Successful "9-month Bangladesh regimen" for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18:1180-7.

Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19:517-24.

World Health Organization (WHO). Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva. 2014. Last accessed date: 01.03.2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_ eng.pdf?sequence=1

Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL; Efficacy Subgroup, RESIST-TB. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis. 2013;207:1352-8.

Gopal M, Padayatchi N, Metcalfe JZ, O"Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013;17:1001-7.

Payen MC, De Wit S, Martin C, Sergysels R, Muylle I, Van Laethem Y, Clumeck N. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16:558-60.

Chang KC, Yew WW, Tam CM, Leung CC. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother. 2013;57:4097-104.

Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012;380:986-93.

Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, PTM (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment:a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385:1738-47.

Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012;16:447-54.

Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508-18.

Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, Wu M, Zen L, Sun H, Liu Y, Gu J, Lin F, Wang X, Zhang Z. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45:161-70.

Koh WJ, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, Shim TS. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother. 2012;67:1503-7.

Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW. Linezolid tolerability in multidrug resistant tuberculosis: a retrospective study. Eur Respir J. 2015;46:1205-7.

Molina-Torres C, Barba-Marines A, Valles-Guerra O, Ocampo-Candiani J, Cavazos-Rocha N, Pucci MJ, Castro-Garza J, Vera-Cabrera L. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages. Ann Clin Microbiol Antimicrob. 2014;13:13.

Yew WW, Koh WJ. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? Korean J Intern Med. 2016;31:15-29.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K. Meropenem-clavulanic acid has high in vitro activity against multidrugresistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:3630-2.

van der Paardt AF, Wilffert B, Akkerman OW, de Lange WC, van Soolingen D, Sinha B, van der Werf TS, Kosterink JG, Alffenaar JW. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. Eur Respir J. 2015;46:444-55.

Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, Lee M, Lee J, Via LE, Lee S, Eum SY, Lee SJ, Goldfeder LC, Cai Y, Jin B, Kim Y, Oh T, Chen RY, Dodd LE, Gu W, Dartois V, Park SK, Kim CT, Barry CE, Cho SN. Efficacy and safety of metronidazole for pulmonary multi-drug resistant tuberculosis. Antimicrob Agents Chemother. 2013;57:3903-9.

Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223-7.

Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:2831-5.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF. Randomized pilot trial of eight weeks of BDQ (TMC207) treatment for multidrug-resistant tuberculosis: longterm outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56:3271-6.

Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371:723-32.

Guglielmetti L, Le Du D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J; MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015;60:188-94.

Stop TB Partnership. Stop TB Partnership"s Global Drug Facility to distribute Bedaquiline (Sirturo) developed by Janssen. Last Accessed date: 10 December 2015. Available from: http://www.stoptb.org/news/stories/2014/ ns14_025.asp

Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3:e466.

Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151-60.

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41:1393-400.

WHO. The use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health.

Davies GR, Phillips PP, Jaki T. Adaptive clinical trials in tuberculosis: applications, challenges and solutions. Int J Tuberc Lung Dis. 2015;19:626-34.

Joint Formulary Commitee. British National Formulary. 69th ed. London: BMJ Group and Pharmaceutical Press. 2015.

Prasad R, Singh A, Srivastava R, Kushwaha R, Garg R, Hosmane GB, Jain A. Adverse drug reaction in treatment of multidrug resistant tuberculosis. Chest. 2013;144:390.

Francis RS, Curwen MP. Major surgery for pulmonary tuberculosis: Final report. Tubercle. 1964;45(Suppl):5-79.

World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008 and 2011. WHO/HTM/TB/2008.402/2011/6. Geneva, Switzerland, 2008/2011. Last accessed date: 01.03.2018. Available from: http://whqlibdoc.who.int/ publications/2008/9789241547581_eng.pdf and http://whqlibdoc.who.int/ publications/2011/9789241501583_eng.pdf

Nitta AT, Iseman MD, Newell JD, Madsen LA, Goble M. Ten-year experience with artificial pneumo-peritoneum for end-stage, drug-resistant pulmonary tuberculosis. Clin Infect Dis. 1993;16:219-22.

Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. WHO guidelines for the programmatic management of drugresistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516-28.

Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrugresistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-92.

Yew WW, Lange C. Fluoroquinolone resistance in Mycobacterium tuberculosis: what have we learnt? Int J Tuberc Lung Dis. 2014;18:1-2.

Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, Squire SB, Madan J, Meredith SK. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;15:353.

World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.23. Geneva, Switzerland, 2014. Last accessed date: 27 February 2015. Available from: http://www. who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb/en/

Sinclair D, Abba K, Grobler L, Sudarsanam TD. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev. 2011;11:1-139.

Prasad R, Verma SK, Sahai S, Kumar S, Jain A. Efficacy and safety of kanamycin, ethionamide, PAS, and cycloserine in multidrug resistant pulmonary tuberculosis patients. Ind J Chest Dis Allied Sci. 2006;48:183-6.

Zumla A, Maeurer M; Host-Directed Therapies Network (HDT-NET) Consortium. Host-directed therapies for tackling multi-drug resistant tuberculosis: learning from the Pasteur-Bechamp debates. Clin Infect Dis. 2015;61:1432-8.

Zumla A, Rao M, Parida SK, Keshavjee S, Cassell G, Wallis R, Axelsson- Robertsson R, Doherty M, Andersson J, Maeurer M. Inflammation and tuberculosis: host directed therapies. J Intern Med. 2015;277:373-87.

Zumla A, Chakaya J, Centis R, D"Ambrosio L, Mwaba P, Bates M, Kapata N, Nyirenda T, Chanda D, Mfinanga S, Hoelscher M, Maeurer M, Migliori GB. Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015;3:220-34.

Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Woodward NJ, Venton TR, Barnes KE, Mullett CJ, Coussens AK, Rutterford CM, Mein CA, Davies GR, Wilkinson RJ, Nikolayevskyy V, Drobniewski FA, Eldridge SM, Griffiths CJ. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377:242-50.

Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AI, Maeurer M. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir Med. 2014;2:301-20.

Etemadi A, Farid R, Stanford JL. Immunotherapy for drug-resistant tuberculosis. Lancet. 1992;340:1360-1.

Stanfort JL. Frontiers in mycobacteriology. Symposium sponsored by National Jewish Center for Immunology and Respiratory Medicine, Vail, Colorado, October, 1997.

Kiran D, Podell BK, Chambers M, Basaraba RJ. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin Immunopathol. 2016;38:167-83.

Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, Trinchieri G, Karp CL. Inhibition of IL-12 production by thalidomide. J Immunol. 1997;159:5157-61.

Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner JD, Rom W, Kaplan G. Thalidomide treatment reduces tumor necrosis factor-alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med. 1995;1:384-97.

Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral L, Dewar RL, Lane HC, Freedman VH, Kaplan G. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:247-57.

Edwards D, Kirkpatrick CH. The immunology of mycobacterial diseases. Am Rev Respir Dis. 1986;134:1062-71.

Singh MM, Kumar P, Malaviya AN, Kumar R. Levamisole as an adjunct in the treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1981;123:277-9.

Patel N, Tripathi SB. Improved cure rates in pulmonary tuberculosis category II (re-treatment) with Mycobacterium w. J Indian Med Assoc. 2003;101:680-2.

Pandie S, Engel ME, Kerbelker ZS, Mayosi BM. Mycobacterium w immunotherapy for treating pulmonary tuberculosis - a systematic review. Curr Pharm Des. 2014;20:6207-14.

Smith I. Stop TB: Is DOTS the answer? Ind J Tub. 1999;46:81-9.

U.S. National Library of Medicine. Last accessed date: 01.03.2018. Available from: https://www.clinicaltrials.gov/ct2/ results?term=cellular+therapy&cond=Tuberculosis

English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett. 2007;110:91-100.

Parida SK, Madansein R, Singh N, Padayatchi N, Master I, Naidu K, Zumla A, Maeurer M. Cellular therapy in Tuberculosis. Int J Infect Dis. 2015;32:32-8.

Gan Y, Wu T, Liu P, Guo S. Characterization and classification of Bo4 as a cluster G mycobacteriophage that can infect and lyse M. tuberculosis. Arch Microbiol. 2014;196:209-18.

Broxmeyer L, Sosnowska D, Miltner E, Chacón O, Wagner D, McGarvey J, Barletta RG, Bermudez LE. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J Infect Dis. 2002;186:1155-60.

D"Ambrosio L, Tadolini M, Centis R, Duarte R, Sotgiu G, Aliberti S, Dara M, Migliori GB. Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. Int J Infect Dis. 2015;32:156-60.

Lunte K, Cordier-Lassalle T, Keravec J. Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility. Bull World Health Organ. 2015;93:279-82.

Qadeer E, Fatima R, Fielding K, Qazi F, Moore D, Khan MS. Good quality locally procured drugs can be as effective as internationally quality assured drugs in treating multi-drug resistant tuberculosis. PLoS One. 2015;10:e0126099.

Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, Knerer G. Costeffectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. PLoS One. 2015;10:e0120763.

Cox H, Ramma L, Wilkinson L, Azevedo V, Sinanovic E. Cost per patient of treatment for rifampicin-resistant tuberculosis in a communitybased programme in Khayelitsha, South Africa. Trop Med Int Health. 2015;20:1337-45.

Li R, Ruan Y, Sun Q, Wang X, Chen M, Zhang H, Zhao Y, Zhao J, Chen C, Xu C, Su W, Pang Y, Cheng J, Chi J, Wang Q, Fu Y, Huan S, Wang L, Wang Y, Chin DP. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Glob Health. 2015;3:217-28.

Portero JL, Rubio M. Private practitioners and tuberculosis control in the Philippines: strangers when they meet? Trop Med Int Health. 2003;8:329-

Gemal A, Keravec J, Menezes A, Trajman A. Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges. BMC Public Health. 2013;13:279.

Médecins Sans Frontières. Out of step: deadly implementation gaps in the TB response. 2014. Last accessed date: 01.03.2018. Available from: http:// www.msf.org/article/out-step-deadly-implementation-gaps-tb-response.

World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: The Organization; 2013. Last accessed date: 01.03.2018. Available from: http:// apps.who.int/iris/bitstream/handle/10665/84879/9789?sequence=1

World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: The Organization; 2014. Last accessed date: 01.03.2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/137334/WHO_HTM_ TB_2014.23_eng.pd?sequence=1

Green Light Committee Initiative. Scaling up the global fight against MDRTB. Annual Report: World Health Organization; 2010. Last accessed date: 01.03.2018. Available from: http://whqlibdoc.who.int/hq/2010/WHO_HTM_ TB_2010.14_eng.pdf

World Health Organization. New global framework to support scale up to universal access to quality management of MDR-TB. Geneva: The Organization; 2011. Available from: https://www.who.int/tb/challenges/ mdr/greenlightcommittee/new_global_framework_summary.pdf

Herrero MB, Ramos S, Arrossi S. Determinants of non adherence to tuberculosis treatment in Argentina: barriers related to access to treatment. Rev Bras Epidemiol. 2015;18:287-98.

Shargie EB, Lindtjorn B. Determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in Southern Ethiopia. PLoS Med. 2007;4:37.

O"Boyle SJ, Power JJ, Ibrahim MY, Watson JP. Factors affecting patient compliance with anti-tuberculosis chemotherapy using the directly observed treatment, short-course strategy (DOTS). Int J Tuberc Lung Dis. 2002;6:307-12.

Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, Mosidi T, Reed C, Seaworth B, Stillo J, Tisile P, von Delft D. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. Int J Infect Dis. 2015;32:56-60.

Shah NS, Brust JC, Mathema B, Mthiyane T, Ismail N, Moodley P, Majority of XDR TB cases are due to transmission in a high-HIV-prevalence setting. Presented at: Conference on Retroviruses and Opportunistic Infections; Seattle, Washington, USA: 2015:23-4.

Snidal SJ, Barnard G, Atuhairwe E, Ben Amor Y. Use of eCompliance, an innovative biometric system for monitoring of tuberculosis treatment in rural Uganda. Am J Trop Med Hyg. 2015;92:1271-9.

Denkinger CM, Grenier J, Stratis AK, Akkihal A, Pant-Pai N, Pai M. Mobile health to improve tuberculosis care and control: a call worth making. Int J Tuberc Lung Dis. 2013;17:719-27.

Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, Jack W, Habyarimana J, Sadatsafavi M, Najafzadeh M, Marra CA, Estambale B, Ngugi E, Ball TB, Thabane L, Gelmon LJ, Kimani J, Ackers M, Plummer FA. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838-45.

Mbuagbaw L, Mursleen S, Lytvyn L, Smieja M, Dolovich L, Thabane L. Mobile phone text messaging interventions for HIV and other chronic diseases: an overview of systematic reviews and framework for evidence transfer. BMC Health Serv Res. 2015;15:33.

Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, MacKeen L, Haberer J, Kimaiyo S, Sidle J, Ngare D, Bangsberg DR. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25:825-34.

Mirsaeidi M, Farshidpour M, Banks-Tripp D, Hashmi S, Kujoth C, Schraufnagel D. Video directly observed therapy for treatment of tuberculosis is patientoriented and cost-effective. Eur Respir J. 2015;46:871-4.

Türkiye Ulusal Verem Savaş Dernekleri Federasyonu. Last accessed date: 01.03.2018. Available from: http://www.verem.org.tr/verem_savasinda_ sorunlar.php